Satsuma Pharmaceuticals, Inc. — Form D/A
Satsuma Pharmaceuticals, Inc. of South San Francisco, CA, a company, filed a Form D amendment with the SEC on 2018-02-12. The offering totals $12.3M, of which $12.1M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-02-12
- Form: D/A
- Accession: 0001692830-18-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $12.3M
- Amount sold: $12.1M
- Remaining: $154K
- Minimum investment: $1
- Investors: 4
- Date of first sale: 2016-12-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-277219
Issuer
- Name: Satsuma Pharmaceuticals, Inc.
- CIK: 0001692830
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 400 Oyster Point Blvd., South San Francisco, CA, 94080
- Phone: 415-505-0809
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Thomas King | Director | Brooklyn, NY |
| John Kollins | Director | South San Francisco, CA |
| Heath Lukatch | Director | Burlingame, CA |
| Michael Riebe | Director | South San Francisco, CA |
| Rajeev Shah | Director | Boston, MA |
| Tadayoshi Iwashima | Executive Officer | South San Francisco, CA |
| John Kollins | Executive Officer | South San Francisco, CA |
Other filings by this issuer (1)
More